Full-Time

Scientist – Oncology Research

Posted on 7/4/2025

Gilead Sciences

Gilead Sciences

10,001+ employees

Develops and commercializes biopharmaceuticals

Compensation Overview

$146.5k - $189.6k/yr

+ Bonus + Stock-based long-term incentives

Mid, Senior

Company Historically Provides H1B Sponsorship

San Mateo, CA, USA

In Person

Category
Diagnostics & Laboratory Professionals
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • PhD degree in related life sciences
  • Master's degree in related life sciences and 4+ years of experience in cell biology, molecular biology, or biochemistry in biotechnology or pharmaceutical industry
  • Bachelor's degree in related life sciences and 6+ years of experience in cell biology, molecular biology, or biochemistry in biotechnology or pharmaceutical industry.
Responsibilities
  • Independently plan, execute, analyze, troubleshoot, and interpret *in vitro* and *ex vivo* experiments that support non-routine research activities and projects goals
  • Proactively evaluate new technologies and develop new assays to accelerate early-stage discovery activities and/or enhance our understanding of disease mechanisms
  • Support multiple projects simultaneously and work cross-functionally with colleagues in the oncology, chemistry, protein engineering, pathobiology, DMPK, biomarker and clinical groups
  • Present research findings and recommendations to senior staff and contribute to preparation of research reports, manuscripts, INDs, and patent filings
  • Provide coaching and training to junior and/or less experienced colleagues in solving technical and scientific problems
Desired Qualifications
  • Master's degree with 8+ years of experience in cell biology, molecular biology, or biochemistry in biotechnology or pharmaceutical industry or Bachelor's degree with 10+ years of experience in cell biology, molecular biology, or biochemistry in biotechnology or pharmaceutical industry.
  • Extensive experience in cancer cell biology, target identification/validation in oncology or immuno-oncology
  • Experience working with small molecules
  • Expertise in cell cycle analysis and high content imaging
  • Extensive experience in general molecular and cell biology methods including primary human and mouse cell culture and basic flow cytometry
  • High proficiency in techniques evaluating cell signaling (e.g. western blot, ELISA, MSD, immunofluorescence, reporter-based assays) and proliferation / survival using small-molecules and biologics
  • Proficiency in methods evaluating gene expression (e.g. RT-qPCR, Nanostring and others)
  • Experience with methods to perturb gene function (e.g. RNAi, CRISPR, overexpression) and to deliver constructs (e.g. transfection, electroporation, lentiviral transduction)
  • Experience with quantitative cellular assays
  • Attention to detail with excellent organizational and record keeping skills
  • Excellent communication and interpersonal skills
  • A strong record of achievements, contributions to drug discovery programs and publications

Gilead Sciences is a biopharmaceutical company that develops and sells medicines for various serious health conditions, including HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular issues. The company focuses on extensive research and development to create new therapies, which are then approved by regulatory authorities before being marketed to healthcare providers, hospitals, and pharmacies. Gilead stands out from its competitors by investing heavily in R&D and forming strategic partnerships, such as with SAP Ariba, to improve its supply chain and ensure sustainable practices. The company's goal is to enhance health equity and access to care, working with communities globally to remove barriers to healthcare and make its medicines available to those in need.

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Simplify Jobs

Simplify's Take

What believers are saying

  • Gilead's oncology navigation grant program enhances its reputation in cancer care.
  • The $11 billion investment is expected to create significant economic value and jobs.
  • Partnerships in innovative cancer treatments position Gilead at the forefront of oncology.

What critics are saying

  • Layoffs and halted expansion plans indicate potential operational challenges in biologics.
  • The $202 million settlement may impact Gilead's financial standing and reputation.
  • Intensifying competition from companies like Amgen pressures Gilead's market performance.

What makes Gilead Sciences unique

  • Gilead's partnership with Kymera focuses on novel cancer treatments using molecular glue degraders.
  • The company invests heavily in R&D, with a $11 billion U.S. investment plan.
  • Gilead's collaborations aim to improve patient outcomes and healthcare access globally.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Company News

Plant Services
Jul 4th, 2025
Factory fallout: Manufacturing plant closures and layoffs from Intel, Hasbro, Johnsonville, and more

According to Fierce Biotech, Gilead Sciences, a pharmaceutical company, is laying off 36 employees as part of a strategic shift that ended plans to expand its biologics facility in Oceanside, California.

Pipeline Review
Jun 26th, 2025
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

Gilead Sciences and Kymera Therapeutics enter into exclusive option and license agreement to develop novel oral molecular glue CDK2 degraders.

24-7 Press Release
Jun 26th, 2025
Gilead Sciences, Inc. proudly Supports Unite for HER's Metastatic Breast Cancer Sustainer Program

PHILADELPHIA, PA, June 26, 2025 /24-7PressRelease/ - Unite for HER (UFH) and Gilead Sciences have partnered to provide a new integrative care program free to Black, Hispanic, and underserved metastatic breast cancer patients in the United States.

BioPharma Dive
Jun 25th, 2025
Kymera adds Gilead as research partner, while advancing new candidate with Sanofi

Gilead and Kymera will develop a molecular glue degrader for breast cancer and other solid tumors.

PR Newswire
Jun 1st, 2025
The Academy Of Oncology Nurse Patient Navigators And Gilead Sciences Partner To Launch Oncology Navigation Grant Program

GAINESVILLE, Fla., June 1, 2025 /PRNewswire/ -- The Academy of Oncology Nurse & Patient Navigators (AONN+) is proud to announce the launch of a groundbreaking grant program in partnership with Gilead Sciences aimed at advancing the field of oncology navigation and enhancing patient outcomes within the healthcare setting. This initiative is designed to support the creation, enhancement, and expansion of innovative tools that optimize efficiency and elevate the critical role of oncology navigators.Following the AONN+ call for grant submissions in April, healthcare leaders across the country responded with creative applications, software solution ideas and healthcare system improvements. AONN+ looks to announce the recipients of the award, valued up to $500,000, in June with project work to begin in the July time frame. The AONN+ grant application process and implementation support for awardees also included help from Amplity, AONN+'s association management partner and strategic collaborator."Through this funding mechanism, AONN+ and Gilead are committed to addressing persistent challenges in cancer care by empowering navigators to play a pivotal role in improving patient access to navigation services, removing barriers to cancer care, and supporting treatment adherence," says Candice Roth, MSN, RN, CENP, Executive Director, AONN+. "Navigator utilization continues to present significant opportunities for optimizing patient outcomes, and this program seeks to provide impactful solutions that directly tie proposed tools to measurable improvements in patient care.""As part of Gilead's Community Cancer Collective, we are proud to partner with AONN+ on this exciting initiative in support of the oncology community," said Darren Tayama, M.D., Vice President, US Medical Affairs, Oncology. "Together, AONN+ and Gilead are advancing the future of cancer care through innovative solutions in oncology navigation."About the Academy of Oncology Nurse & Patient Navigators , Inc

INACTIVE